Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and Positive Cancer Trial Results Boost Optimism

TLDR Moderna stock jumps 7.38% to $259.25 following strong third-quarter results. Quarterly revenue climbs 29% to $1.3 billion as overseas vaccine sales rise. Moderna swings to a $162 million quarterly profit, with EPS reaching $0.38. Moderna lifts its 2026 revenue growth forecast to 15%-25% after strong sales. Phase 3 melanoma data show a 42% drop [...]

The post Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and Positive Cancer Trial Results Boost Optimism appeared first on Blockonomi.